Eli Lilly ແມ່ນການຂະຫຍາຍຕົວທີ່ດີທີ່ສຸດໃນຫ້ອງຮຽນ, ນັກວິເຄາະກ່າວວ່າໃນຂະນະທີ່ເລີ່ມຕົ້ນການຄຸ້ມຄອງ

• Credit Suisse ໄດ້ລິເລີ່ມການຄຸ້ມຄອງກ່ຽວກັບການ Eli Lilly ແລະ Co (NYSE: ມີ) ດ້ວຍ​ການ​ໃຫ້​ຄະ​ແນນ Outperform ແລະ a ເປົ້າ ໝາຍ ລາຄາ 395 ໂດລາ.

• Management has delivered a remarkable performance against a challenging backdrop. However, with the stock at an all-time high valuation, the key question is whether it can continue this momentum.

• The analysts are optimistic and believe that Eli Lilly has industry-leading growth in the short- and long-term, unhampered by loss of exclusivity (LOE).

• ທີ່ກ່ຽວຂ້ອງ: Eli Lilly Says Q3 Earnings Supported By Key Products and Volume, Cuts FY22 Outlook.

• Credit Suisse notes some turbulence if Mounjaro cannot hit short-term quarterly numbers, with supply concerns, but in the long term, it is expected to be one of the most valuable drugs in Pharma.

• Several investors remain offside given the binary donanemab TRAILBLAZER-2 Alzheimer’s Phase 3 data expected in mid-2023, but analysts think the setup is skewed to the upside.

• The analyst believes the Street is underappreciating the obesity market size given the impressive data and favorable reimbursement with Wegovy. Donanemab (Alzheimer’s) should continue to dominate the headlines.

• ລາຄາປະຕິບັດງານ: LLY shares are down 0.23% at $359.93 on the last check Friday.

Latest Ratings for LLY

ວັນທີ່ສະຫມັກ	ບໍລິສັດ	ການປະຕິບັດ	From	To
Feb 2022	Morgan Stanley	ຮັກສາ		Overweight
Feb 2022	Mizuho	ຮັກສາ		ຊື້
Jan 2022	Morgan Stanley	ຮັກສາ		Overweight

View More Analyst Ratings for LLY

ເບິ່ງຄະແນນການວິເຄາະຫຼ້າສຸດ

ເບິ່ງເພີ່ມເຕີມຈາກ Benzinga

ຢ່າພາດການແຈ້ງເຕືອນແບບສົດໆໃນຫຸ້ນຂອງເຈົ້າ – ເຂົ້າຮ່ວມ Benzinga Pro ສໍາລັບການຟຣີ! ລອງໃຊ້ເຄື່ອງມືທີ່ຈະຊ່ວຍໃຫ້ທ່ານລົງທຶນຢ່າງສະຫຼາດຂຶ້ນ, ໄວຂຶ້ນ, ແລະດີກວ່າ.

©ປີ 2022 Benzinga.com. Benzinga ບໍ່ໃຫ້ ຄຳ ແນະ ນຳ ດ້ານການລົງທືນ. ທິການ.